Hepcvel Tablet Cipla sofosbuvir 400 mg velpatasvir 100 mg bottle of 28 tablets
Hepcvel Tablet
$627.99 Original price was: $627.99.$438.99Current price is: $438.99. Select options
Sale!

Hepcvel Tablet

Original price was: $627.99.Current price is: $438.99.

-30%

Sofosbuvir 400 mg + Velpatasvir 100 mg from Cipla, a pangenotypic hepatitis C treatment covering all six genotypes. Bottle of 28 tablets. Prescription required.

  • Free Shipping: On orders of $149 USD

Order by Email or WhatsApp

Send us the product name & quantity — our team replies quickly.

Hepcvel Tablet тАУ Sofosbuvir 400 mg + Velpatasvir 100 mg by Cipla

Hepcvel Tablet from Cipla Ltd. combines Sofosbuvir 400 mg with Velpatasvir 100 mg тАУ a pangenotypic direct-acting antiviral pairing that treats all six hepatitis C genotypes without needing genotype testing first. Sofosbuvir blocks the NS5B polymerase the virus uses to copy its genome, while Velpatasvir inhibits the NS5A protein it needs to assemble new virus particles. Attacking two separate steps at once is what makes cure rates above 95% achievable in a 12-week course, and it leaves the virus little room to develop resistance. Bottle of 28 tablets тАУ four weeks of therapy.

Key Features

  • Sofosbuvir 400 mg + Velpatasvir 100 mg fixed-dose combination
  • Pangenotypic тАУ effective across all six HCV genotypes
  • One tablet daily, with or without food
  • Bottle of 28 tablets тАУ one month of a typical 12-week course
  • From Cipla Ltd., a WHO-prequalified Indian manufacturer

Composition

  • Sofosbuvir тАУ 400 mg (NS5B polymerase inhibitor)
  • Velpatasvir тАУ 100 mg (NS5A inhibitor)

Uses & Benefits

  • Treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and over
  • Effective across all six HCV genotypes тАУ no genotype testing needed before starting
  • Clears the virus from the blood in over 95% of patients on a completed course
  • Can be used in compensated cirrhosis, and with ribavirin in decompensated disease
  • Reduces the long-term risk of liver failure and liver cancer once the virus is cleared
  • Simple one-tablet-a-day regimen, typically for 12 weeks

Directions for Use

  • Take exactly as prescribed тАУ usually one tablet once daily for 12 weeks
  • Swallow the tablet whole with water; do not chew, crush or break it
  • May be taken with or without food, but take it at the same time every day
  • Complete the full course even when you feel well тАУ stopping early risks relapse and resistance
  • If you miss a dose, take it as soon as you remember unless the next is near; never double up

Precautions

  • You must be tested for hepatitis B before starting. HBV can reactivate during HCV treatment and cause serious, sometimes fatal, liver injury тАУ your doctor will screen and monitor for this
  • Do not take with amiodarone тАУ the combination can cause severe, potentially fatal slowing of the heart
  • Tell your doctor about all other medicines, especially rifampicin, carbamazepine, phenytoin, St JohnтАЩs Wort, certain HIV medicines and antacids, which can make this treatment fail
  • Common side effects include headache, tiredness, nausea, diarrhoea, insomnia and anaemia
  • Use with caution in severe kidney disease; liver function is monitored throughout treatment
  • Avoid alcohol; it may cause dizziness or blurred vision, so do not drive until you know how it affects you

Storage

  • Store below 30┬░C in a dry place
  • Keep in the original bottle with the cap tightly closed; protect from light and moisture
  • Keep out of reach of children

Disclaimer

Prescription medicine тАУ not to be sold by retail without the prescription of a Registered Medical Practitioner. This information is for general awareness only and is not a substitute for professional medical advice, diagnosis or treatment. Hepatitis C therapy must be started and monitored by a qualified hepatologist or physician, with the appropriate baseline tests.

Reviews

There are no reviews yet.

Be the first to review “Hepcvel Tablet”

Your email address will not be published. Required fields are marked *